Insights Into Chronic Lymphocytic Leukemia (CLL) – Northwest

Perspectives of community physicians from the northwest region of the United States on the management of newly diagnosed and relapsed/refractory CLL

Northwest – November 9, 2020

Faculty Chair

John M. Pagel, MD, PhD

Swedish Cancer Institute, Seattle, WA, US

Example Report

Start discovering the insights

View Report


  • Insights from a moderated roundtable discussion focusing on treatment of CLL
  • Insights on the following CLL therapies: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, BR
  • Data collected via audience response system questioning and in-depth moderated discussion


  • The group of advisors comprised 10 community oncologists from the northwest region of the United States

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.